Friday, January 24, 2020 12:32:03 PM
40 Recurrent #Glioblastoma patients will get #DCVax-L in new clinical trial. Updated to "Recruiting" on January 15, 2020. Eligible patients will receive either DCVax-L & #Keytruda or DCVax-L alone @UCLAJCCC.
@KristynPower @Sclavicus $nwbo $mrk #GBM #Hope
https://clinicaltrials.gov/ct2/show/NCT04201873
40 Recurrent #Glioblastoma patients will get #DCVax-L in new clinical trial. Updated to "Recruiting" on January 15, 2020. Eligible patients will receive either DCVax-L & #Keytruda or DCVax-L alone @UCLAJCCC.@KristynPower @Sclavicus $nwbo $mrk #GBM #Hopehttps://t.co/Z81zHeEbuP pic.twitter.com/OFM82kXSX0
— rj (@sharpie510) January 24, 2020
Recent NWBO News
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
